Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Khorrami M, Prasanna P, Gupta A, Patil P, Velu PD, Thawani R, et al. Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer. Cancer Immunol Res. 2020;8(1):108-119.

Holst JM, Plesner TL, Pedersen MB, Frederiksen H, Møller MB, Clausen MR, et al. Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort. Haematologica. 2020;105(10):2432-2439.

Kudo Y, Sugimoto M, Arias E, Kasashima H, Cordes T, Linares JF, et al. PKCλ/ι Loss Induces Autophagy, Oxidative Phosphorylation, and NRF2 to Promote Liver Cancer Progression. Cancer Cell. 2020;38(2):247-262.e11.

Alam T, Agrawal S, Severin J, Young RS, Andersson R, Arner E, et al. Comparative transcriptomics of primary cells in vertebrates. Genome Res. 2020;30(7):951-961.

Haas T, Cushing MM. Hemostatic Balance in Severe Trauma. Front Pediatr. 2020;8:600501.

Aslanidou L, Trachet B, Sasset L, Lovric G, Stergiopulos N, Di Lorenzo A. Early Morphofunctional Changes in AngII-Infused Mice Contribute to Regional Onset of Aortic Aneurysm and Dissection. J Vasc Res. 2020;57(6):367-375.

Amara SN, Kuiken HJ, Selfors LM, Butler T, Leung ML, Leung CT, et al. Transient commensal clonal interactions can drive tumor metastasis. Nat Commun. 2020;11(1):5799.

Geyer JT, Margolskee E, Krichevsky SA, Cattaneo D, Boiocchi L, Ronchi P, et al. Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression. Haematologica. 2020;105(5):e221-e224.

Nuovo GJ, Magro C, Mikhail A. Cytologic and molecular correlates of SARS-CoV-2 infection of the nasopharynx. Ann Diagn Pathol. 2020;48:151565.

Lui GY, Shaw R, Schaub FX, Stork IN, Gurley KE, Bridgwater C, et al. BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. EBioMedicine. 2020;60:102988.